Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
Michael Beatrice named VP-corporate and regulatory science, effective Nov. 1. Beatrice, who has 25 years of regulatory affairs experience having previously held positions in FDA's drugs and biologics centers, could prove valuable in upcoming discussions with the agency about recent compliance problems in the firm's diagnostics division (1"The Gray Sheet" Oct. 4, p. 16). Meanwhile, Abbott acquisition target Perclose has postponed to Nov. 19 its shareholders meeting to consider the combination, citing the uncertainty of the outcome of Abbott's discussions with FDA